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A B S T R A C T
The opioid crisis presents substantial challenges to public health in New England's rural states, where access to
pharmacotherapy for opioid use disorder (OUD), harm reduction, HIV and hepatitis C virus (HCV) services vary
widely. We present an approach to characterizing the epidemiology, policy and resource environment for OUD
and its consequences, with a focus on eleven rural counties in Massachusetts, New Hampshire and Vermont
between 2014 and 2018. We developed health policy summaries and logic models to facilitate comparison of
opioid epidemic-related polices across the three states that could influence the risk environment and access to
services. We assessed sociodemographic factors, rates of overdose and infectious complications tied to OUD, and
drive-time access to prevention and treatment resources. We developed GIS maps and conducted spatial analyses
to assess the opioid crisis landscape. Through collaborative research, we assessed the potential impact of
available resources to address the opioid crisis in rural New England. Vermont's comprehensive set of policies
and practices for drug treatment and harm reduction appeared to be associated with the lowest fatal overdose
rates. Franklin County, Massachusetts had good access to naloxone, drug treatment and SSPs, but relatively high
overdose and HIV rates. New Hampshire had high proportions of uninsured community members, the highest
overdose rates, no HCV surveillance data, and no local access to SSPs. This combination of factors appeared to
place PWID in rural New Hampshire at elevated risk. Study results facilitated the development of vulnerability
indicators, identification of locales for subsequent data collection, and public health interventions.
1. Introduction
New England states experienced a surge in synthetic opioid deaths
with the introduction of illicit fentanyl in 2013–15 (Rudd et al., 2016;
Gladden et al., 2016; Somerville et al., 2017). In 2016, Vermont (VT),
New Hampshire (NH), and Massachusetts (MA), were among the top 10
states in the U.S. for opioid overdose death rates, and NH (30.3 per
100,000) and MA (23.5 per 100,000) had the 1st and 3rd highest rates
for fatal overdoses attributed to fentanyl (DEA, 2018). Hepatitis C virus
(HCV) infection rates have increased along similar trajectories
(Thakarar et al., n.d.), and recent human immunodeficiency virus (HIV)
clusters among people who inject drugs (PWID) in MA have raised
concerns about widespread outbreaks (Schumaker, 2018; Cranston
et al., 2019).
The devastating outbreak of HIV and HCV among PWID in Scott
County, Indiana (Conrad et al., 2015), raised the alarm about injection
drug use (IDU) in rural areas where geographic dispersion, poor
transportation, and limited public health infrastructure constrained the
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delivery of preventive and treatment services (Conrad et al., 2015). As a
result, the Centers for Disease Control and Prevention (CDC) has
identified a number of rural U.S. counties vulnerable to HIV and HCV
(Van Handel et al., 2016). The changing terrain with regard to pre-
scription opioids in rural communities (Conrad et al., 2015; Broz et al.,
2018; Peters et al., 2016), and the entry of fentanyl into local drug
supplies (Somerville et al., 2017), have dramatically increased the risk
for opioid overdose in rural communities, where access to harm re-
duction services is limited. Little is known about the epidemiology,
service access, and policies that contribute to the local risk environ-
ment.
To address the opioid crisis, novel approaches are needed to reduce
overdose deaths and infectious diseases associated with IDU. Unsafe
injection practices among PWID are associated with increased in-
fectious complications and mortality tied to HIV, HCV, the hepatitis B
virus (HBV) (Prevention CfDCa, 2012; Zibbell et al., 2015; Ly et al.,
2016), major bacterial infections (Gordon and Lowy, 2005; Wurcel
et al., 2016), and opioid overdose (Rudd et al., 2016).
Little research has examined the epidemiology of IDU, its infectious
disease and opioid overdose consequences, and service accessibility in
rural New England. A better understanding of these factors is crucial to
develop community and public health best practices to reach PWID in
these rural communities.
This article documents our approach to studying the impact of the
opioid epidemic in rural New England, the health policy and legal
landscape that surrounds it, and the ability of PWID to access services
that could help curb the epidemic and reduce the risk of spreading
infectious diseases. Our overall objectives were to: 1) Assess the state
and local policy environment and infrastructure, including access to
syringe service programs (SSPs), drug treatment, naloxone, and HIV
and HCV testing, prevention, and treatment services; and 2) char-
acterize the risk environment and epidemiology of opioid overdose and
infectious complications tied to IDU, as well as service needs in these
counties.
2. Methods
As part of a federally-funded multisite initiative, our team con-
ducted an epidemiological and policy assessment of opioid-related
outcomes, prevention and care services, and laws in eleven contiguous
rural counties in Northwestern MA (Franklin County), Eastern VT
(Windham, Windsor, Orange, Caledonia, Essex and Orleans Counties),
and Western NH (Cheshire, Sullivan, Grafton, and Coos Counties) lo-
cated along the Interstate 91 corridor and the Connecticut River. All
selected counties were defined as rural counties according to federal
definitions (HRSA, 2016). Several of these rural counties, located on the
border between NH and VT (Fig. 4a) (HRSA, 2016), are identified as
high risk for HIV and HCV outbreaks among PWID (Van Handel et al.,
2016).
Our Epidemiology, Policy and Law workgroup included state public
health professionals, academicians, harm reduction experts, and field
researchers. Our team met biweekly over the course of one year via
videoconference. Through virtual meetings, email correspondences,
and the sharing of surveillance measures, reports, and outcome data,
we developed and refined definitions of key opioid epidemic measures.
We came to consensus on the variables and definitions for the infectious
disease and opioid overdose measures that were to be compiled and
aggregated across the 11 counties in all three states. We developed data
dictionaries and data table shells that collaborative team members
filled. When data were available for all 11 counties across our three
states, we merged the data into one dataset for GIS mapping and ana-
lysis. The team also participated in and led discussions and efforts to
find new measures that could be compiled and analyzed consistently
across eight federally funded rural opioid study sites.
2.1. Health policy tables and logic models
Using policy data from state statutes and regulations on-line, sup-
plemented by inquiries to state policy experts, we characterized the
legal and policy landscape in VT, NH, and MA in March–April 2018
with respect to the opioid epidemic. Policy analyses focused primarily
on syringe and naloxone access, Good Samaritan laws, Prescription
Drug Monitoring Programs (PDMP), HIV and HCV Surveillance and
Treatment, and substance use disorder treatment access. Other com-
ponents captured included: justice reinvestment, heroin trafficking,
health insurance coverage, mental health care and care coordination,
prescription drug disposal, opioid use disorder (OUD) treatment access,
fentanyl, and medication access in prison. Salient policy landscape
findings related to fatal overdose and HCV transmission were identified,
summarized, and connected to their associated process points. We de-
veloped policy tables that allow a comparative assessment of salient
opioid epidemic policies and laws (Table 1; Supplemental Table 1).
Next, we created logic models to describe relationships and important
variables in complex systems and to allow our team to understand and
describe assumptions, as well as consider potential relationships be-
tween policies, laws, and health outcomes. Our logic models outline the
environmental, enabling, and inhibiting factors (e.g., policies, laws,
public health interventions) that influence key outcomes of the opioid
epidemic in the state specific context.
2.2. Geographic Information System (GIS) mapping and spatial analysis
Using census tract level population denominators and socio-
demographic data from the American Community Survey (ACS) (United
States Census Bureau, n.d.), we generated thematic maps in a GIS for
sociodemographic variables (e.g., unemployment rates, median income,
insurance rates, percent non-white), opioid syndemic burden outcomes,
as characterized by opioid overdose, HIV, and HCV rates, and avail-
ability of harm reduction, drug treatment, and overdose prevention
services (SSPs, pharmacies, medication for opioid use disorder, na-
loxone). We aggregated disease burden rates at the county level across
our 11 study counties. Infectious disease surveillance data for HIV,
HCV, and sexually transmitted infections (STIs), as well as opioid
overdose data, were provided by collaborating public health officials,
and compiled from publicly available reports and websites. We focused
on the three most current and complete years of data at the time we
initiated collaborative efforts—2014 to 2016. We categorized rates by
quintiles. We geocoded address-level data for prevention and treatment
resources from data compiled from department of public health web-
sites, State Boards of Pharmacy, State Epidemiologists, and other pub-
licly available databases. We conducted drive-time analyses using a
network analyst tool in a GIS that relies on street networks across MA,
VT, and NH, to identify 5, 15, 30, and>30-minute drive-sheds to as-
sess geospatial access to key services. Drive-times were calculated from
the address of the service sites, taking into consideration speed limits,
terrain, and one way streets. All GIS maps and spatial analyses were
completed with ArcGIS 10.6.1 and ArcGIS Pro 2.2 (Esri, Redlands, CA).
3. Results
3.1. Health policy table and logic models
The results of our health policy analysis resulted in a multi-state
policy table that provides comparative details on opioid epidemic re-
lated policies across NH, VT, and MA. Our final policy analyses are
summarized in logic models focused on fatal opioid overdose (Fig. 1)
and HCV transmission (Fig. 2). We developed similar models for each
outcome across each of our three study states, and we present two ex-
amples here.
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3.2. Fatal overdose in New Hampshire
Factors that contributed to fatal opioid overdose in NH included: 1)
a minimal state tax base to fund services in the absence of income and
sales taxes; 2) the absence of legal SSPs prior to June 2017; 3) primarily
abstinence-based treatment; and, 4) limited access to complex co-
morbid mental health and medical care. Key policies that can facilitate
or inhibit OUD and overdose include: PDMP policy; access to OUD
services; murder charges for fentanyl deaths; limited access to medi-
cation in corrections; growth of drug court programs; naloxone access;
and the Good Samaritan law. Despite the Good Samaritan law, prose-
cutors have still pursued charges for fatal overdose if the caller pro-
vided fentanyl to the deceased. Prominent process points include: level
of OUD, comorbidities that amplify the effect of opioids, access to street
drugs, fentanyl on the street, and opioid tolerance. From a policy per-
spective, fatality is most related to access to naloxone and fear of
criminal charges related to calling 911 if the overdose results in a
fatality (Fig. 1).
3.3. HCV transmission in Vermont
Salient background factors that contributed to HCV transmission in
VT (Fig. 2) included 1) stigma, 2) lack of awareness of infection status
or risk, 3) legal jeopardy, and 4) drug use behaviors. The diversion of
opioids in healthcare settings is a possible contributor, although little is
known about how often this occurs. From a policy perspective, VT has
Table 1
Policy summary for Vermont, New Hampshire and Massachusetts, 2018.⁎
Policy Vermont Massachusetts New Hampshire
Syringe access Permitted since 1998
Typically open only a few hours per week
Permitted since 1993
Typically open during business hours
Permitted since 2017
None in the study region
Naloxone access Updated 2016 statewide standing order and
immunity from liability
Updated 2018 to enhance access in pharmacies
through required standing order
Updated 2015 to allow for standing orders and
immunity from liability
Good Samaritan legal
protections for people
who seek medical
assistance
Present
18 V.S.A. § 4254
Present
M.G.L. part III, title IV, chapter 258C section 13
Present
318-B:28-b
Prescription drug
monitoring program
Since 2009
18 V.S.A. § 4287
Modified in 2016 M.G.L. part I title XV chapter
94C section 24A
Since 2016
House Bill 1423
Hepatitis C surveillance Reportable infection during study period Reportable infection during study period Reportable infection since 2017
Hepatitis C treatment access
with Medicaid coverage
No sobriety restrictions, no fibrosis score
required, requires specialist consultation
No sobriety restrictions, no fibrosis score
required, primary care providers may initiate
treatment without specialist consultation
No abstinence-based criteria, but screening and
counseling for substance use required prior to
treatment initiation, requires specialist
consultation
Substance use disorder
treatment access
VDH rules governing medication-assisted
therapy establish minimum requirements for
authorized office based opioid treatment
Providers to prescribe and dispense
buprenorphine, as well as Vermont-specific
requirements for opioid treatment programs
that are in addition to the regulatory
requirements of 42 CFR, part 8.
Multiple statutes address treatment access and
eliminate requirement for preauthorization,
support the expansion of services, mandate
evaluation within 24 h of emergency
department visit for overdose, require effective
discharge planning, require coverage for FDA
approved drugs for opioid or alcohol
dependence
Multiple statutes eliminate requirement for
preauthorization for outpatient treatment, with
time limits on inpatient preauthorization,
expands access to treatment through drug
courts
⁎ A more detailed policy summary is provided in Supplemental Table 1, which includes links to additional statutes and law.
Fig. 1. Logic model for fatal opioid overdose in New Hampshire, 2018. Relevant state laws and state policies and practices are highlighted in gray boxes. Key
components of the causal diagram, “overdose process points”, are highlighted in white boxes in the center of the diagram. Background factors tied to opioid overdose
in New Hampshire are highlighted in the box outlined with hashed lines on the left-hand side of the figure.
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robust laboratory surveillance data on HCV infections, and treatment is
readily accessible for those with Medicaid. SSPs are available, although
access in many rural parts of the state is limited. Possession of needles
and syringes as part of an SSP is legal in VT; HCV transmission ulti-
mately occurs due to a lack of sterile injection practices.
3.4. GIS maps and spatial analyses
In our initial GIS maps, we examined social determinants of health.
NH had the highest percentage of uninsured persons, followed by VT
and MA. Median income was lowest in the northern-most census tracts
of Northern New England. The non-white population was higher in
highly populated areas, while unemployment rates had no regular
pattern. These maps highlight disparities in the region that may be
associated with opioid syndemic burden and service access (Fig. 3).
Fatal opioid overdose, HIV, and HCV rates varied across the study
area (Fig. 4). In 2015, opioid fatality rates were 23.3 (MA), 31.3 (NH),
and 13.4 (VT) per 100,000 (Fig. 4b). While fatal opioid overdose were
relatively low in Grafton County, NH and Caledonia County, VT, New
Hampshire as a whole saw a 2.5-fold increase in opioid deaths between
2010 and 2015 (data not shown). NH had no SSPs until 2017, and
throughout the study area, counties without SSPs before 2017 experi-
enced relatively high opioid fatality rates. Franklin County, MA had an
opioid fatality rate per 100,000 of 14.1 in 2014, 19.7 in 2015, and 21.3
in 2016. Orange County, VT saw an increase in the opioid fatality rate
over three years, although the numbers of deaths were low (Fig. 4b),
and rates may be less stable due to small population sizes. We also
observed an increase in non-fatal opioid overdoses in Franklin County,
MA and Cheshire County, NH (data not shown).
In Southern Vermont counties, rates per 100,000 for people living
with HIV/AIDS increased between 2014 and 2016 (Fig. 4c). We also
noted persistently high HCV rates in Windsor and Windham County, VT
(Fig. 4d). Further, we identified locations where data were not readily
available. In NH, for instance, HCV was not a reportable disease until
2017, so we were unable to map HCV rates in NH counties.
Mobile and brick and mortar SSPs were accessible within our rural
study counties in VT and MA, but SSPs only became legal in NH in
2017. Efforts were underway to open SSPs in Sullivan and Cheshire
Counties in early 2019. Drug treatment and naloxone were relatively
accessible along Interstate 91 within 5, 15, and 30-minute drive-times
(Fig. 5). Regions within our rural study counties that were distant from
major highways had less access to drug treatment and naloxone (Essex
and Orange, VT; Coos and Grafton, NH), and drive-times to pharmacies
with a naloxone standing order in most regions of Franklin County, MA
and Cheshire and Sullivan Counties, NH were 30min or less, high-
lighting good overall access (Fig. 5).
4. Discussion
Our multi-state, interdisciplinary collaborative team developed a
multifaceted approach to assess the opioid epidemic landscape across
11 rural Northern New England counties. Health policy summaries and
logic models facilitated comparison of opioid epidemic-related polices
and “laws on the books” across our three focal states that could influ-
ence the risk environment and access to services in our eleven study
counties. GIS maps and spatial analyses provided an initial picture of
the opioid crisis landscape in rural New England.
Health policy logic models assessed environmental, inhibiting, and
enabling factors to opioid epidemic outcomes, as well as public health
and public safety policies that could address such outcomes. Our logic
models were created to understand the interrelationships between en-
abling environmental and legal factors related to disease risks and
outcomes, and that could inform next steps in efforts to curtail the most
detrimental outcomes tied to the opioid crisis.
Previous research has presented a range of geospatial approaches to
assess the risk environment tied to injection drug use (Cooper et al.,
2009), and mixed methods to assess the social geography of disease risk
(Singer et al., 2000). In juxtaposing sociodemographic, infectious dis-
ease, and opioid overdose maps, we were able to identify locations
where the social determinants of health and higher disease burdens
were most concerning, helping to inform selection of locales for sub-
sequent qualitative and quantitative primary data collection activities.
Fig. 2. Logic model for HCV transmission in Vermont, 2018. Relevant state laws, policies and practices are highlighted in gray boxes. Key components of the causal
diagram, “HCV transmission process points”, are highlighted in white boxes in the center of the diagram. Background factors tied to HCV transmission in VT are
highlighted in the box outlined with hashed lines on the left-hand side of the figure.
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We were also able to obtain an early indication of regions and com-
munities that might be at greatest need for public health and clinical
interventions to curb opioid syndemic outcomes. In NH, for instance,
we noted higher proportions of uninsured community members (per-
haps tied to the lower tax base), some the highest opioid overdose rates,
a lack of HCV surveillance data (HCV became reportable in 2017), and
no local access to SSPs. This combination of factors appears to place
PWID in rural New Hampshire at exceptionally high risk.
Our approach can be replicated elsewhere in the U.S. and other
regions of the world where the opioid crisis has presented challenges.
Work with a multidisciplinary and cross-sectoral team of state public
health professionals, academic researchers, and community-based ex-
perts is essential. Inclusion of local GIS and spatial analysis experts
across sites is also recommended, to facilitate development of consistent
maps for cross-site comparison in an efficient manner.
Opioid surveillance measures have been recently recommended
(Council of State and Territorial Epidemiologists (CSTE), 2017) in the
U.S. The CDC has also recently funded 41 states to conduct opioid
epidemic jurisdiction vulnerability analyses that build upon the ap-
proach developed by Van Handel et al. (2016), and aims to guide col-
lection and analysis of consistent measures at a comparable unit of
analysis (e.g., state, county, municipality) across many regions of the
U.S. The results of those analyses can be supplemented by epidemio-
logic and policy assessments like the one described here to best inform
approaches to decrease morbidity and mortality associated with sub-
stance use disorder.
Fig. 3. Sociodemographic characteristics of Vermont, New Hampshire, Massachusetts census tracts in 11 rural study counties, 2011–2016. a) Percent of population
non-white (class breaks by quintiles); b) median household income in 2016 inflation adjusted dollars (quintiles); c) percent of population age 16 years or older who
were unemployed (quintiles); d) Percent of population age 18–64 years who were uninsured (quintiles).
a b
c d
Fatal Opioid Overdose Rates
PLWHA Rates HCV Rates
Fig. 4. Geospatial distributions of opioid syndemic outcomes in 11 rural New England counties in Massachusetts, New Hampshire, and Vermont, 2014–2016. Study
counties for the Drug Injection Surveillance and Care Enhancement for Rural Northern New England (DISCERNNE) project (a); fatal opioid overdose rates per
100,000 population (b); people living with HIV/AIDS (PLWHA) rates per 100,000 (c); HCV rates per 100,000 (d).
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This approach has several limitations. Data were not complete for
all variables and measures of interest across all three states and all 11
counties. Through our collaborative team meetings and calls, we aimed
to focus on the outcomes for which we had access to consistent sur-
veillance data and measures in all sites. Many measures were not
available across all 11 county sites, which provided limited geospatial
granularity across our study region. Small numbers in the numerators
and denominators can also lead to large fluctuations in rates across
rural counties with small population counts. When available, we com-
plemented such maps with maps of local measures at the sub-county
level. Cross-state sharing of data (e.g., PDMP) is not typically possible.
Naloxone distribution data and administration were not consistently
a b 
c d 
Fig. 5. Geospatial access to opioid syndemic services in Massachusetts, Vermont and New Hampshire, 2017–2018. Drive-time access (5, 15, 30, and > 30min) to
syringe service programs (a); drive-time access (5, 15, 30,> 30min) to drug treatment programs (b); drive-time access (5, 15, 30,> 30min) to naloxone distribution
sites at pharmacies, community agencies, and health centers (c); spatial access (5, 10, 30,> 30miles) to naloxone distribution sites at Vermont community and
pharmacy sites (d).
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available across all counties, and these results include only pharmacy
access to naloxone. Cross-border interactions could also influence ac-
cess to services. We are unable to draw causal inferences from our
policy, law, and geospatial data.
4.1. Lessons learned
Through our three-state epidemiology, policy and law workgroup
collaboration, we garnered several key lessons that will help inform
subsequent collaborative work. We found that the composition of the
work group is key to success, and the decision making process with
regard to selection of measures and final aggregation of data benefitted
from discussion among state public health professionals and academic
partners. This multidisciplinary approach facilitated opportunities to
assure that we selected measures that were available across all three
states, and our eleven study counties. A range of content area expertise
was also essential, with key contributions from state officials with ex-
pertise in infectious disease and opioid overdose surveillance systems
and nomenclature. This range of expertise from a content, technical,
and surveillance perspective, also facilitated access to relevant local,
state, and federal reports and guidance documents from other jur-
isdictions and agencies that contributed. The work of the CSTE, which
has focused on development of consistent opioid epidemic measures,
provided solid resources for definition of measures and consistent data
sources across states.
Regularly scheduled videoconferences and email correspondence,
including document sharing, were essential to the success of our work,
as we were able to consistently convene key experts in each state to
continue our decision making processes with regard to selection and
definitions of key measures. By leveraging existing relationships and
data sources, instead of reinventing the wheel, we were able to take
advantage of connections and find the right people to address key re-
quests.
Selection of measures requires that collaborative teams pay close
attention to several key issues: 1) availability of data sources; 2) con-
sistency of measures; and 3) ease of access to data. With regard to data
sources, variations in public health policy can influence whether certain
surveillance systems exist. While HCV surveillance data were available
in MA and VT, HCV only became a reportable disease in NH in 2017,
and HCV surveillance data were not available for NH during our study
timeframe. Consistency of measures, and especially rate calculations
that normalize by population, were facilitated by use of consistent data
sources across sites, and reliance on state or federal definitions for key
outcomes (where available). Access to data was fostered by key colla-
borative team members who worked within local and state health de-
partments. State epidemiologists tended to have a particularly strong
understanding of the available datasets and measures across various
agencies and divisions within state and federal agencies.
4.2. Recommendations
Based on the CSTE recommended measures and our own experience
collaborating with a wide range of public health and clinical experts,
we recommend that future opioid epidemiologic scans focus on the
following data sources and measures: HIV surveillance data (rates for
PLWH and for PLWH with IDU risk), hepatitis surveillance data in-
cluding differentiation of acute viremia or chronic disease, fatal opioid
overdose rates, naloxone distribution locales and distribution methods,
STI surveillance data (syphilis, gonorrhea, and chlamydia rates), state
alcohol and substance use treatment capacity and availability, and so-
cial determinants of health such as homelessness.
We also recommend formation of multidisciplinary and multi-sec-
torial teams that fosters collaborative work with state public health
professionals, academic researchers, and community-based experts, to
identify, define, and measure key outcomes in a consistent manner
across state-level and multi-state regions. Inclusion of state
epidemiologists, where possible, is strongly recommended for similar
future efforts. Standardized surveillance indicators, such as those re-
commended by the CSTE, should be used across sites to allow for cross-
site comparisons and analysis of trends over time. Inclusion of local GIS
and spatial analysis experts across sites is also recommended, to facil-
itate development of consistent maps for cross-site comparison in an
efficient manner.
5. Conclusion
This study provides an initial understanding of the epidemiological,
legal, and policy landscape related to the opioid crisis in rural Northern
New England and serves as a model on how states can form multi-
disciplinary teams from the public and private sectors, utilizing epi-
demiological and policy analyses and scans to understand the effect that
social vulnerabilities and related comorbid medical conditions have on
PWIDs. This approach includes the etiology, progression and main-
tenance of these conditions, creating demographic profiles and identi-
fying priority areas to better target limited resources and improve in-
tervention design, quality and outcomes. It can be replicated in other
regions of the U.S., and for a range of public health issues. Study results
also provided information to guide next steps in a larger project, in-
cluding locations for recruitment of active opioid users and locales for
future interventions.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.ypmed.2019.05.028.
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